N/A Completed N=23 Treatment

Stereotactic Body Radiotherapy for Liver Tumors

Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma

Source: ClinicalTrials.gov NCT01347333 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2020

Primary outcomePrimary: Local Tumor Recurrence Rate — 4; 0 Participants

Summary

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Outcome Measures

Outcome	Result	p-value
PRIMARY Local Tumor Recurrence Rate	4; 0	—
SECONDARY Late Complication Rates	—	—

Eligibility Criteria

Inclusion Criteria

Patient age >= 18 years
Zubrod performance status of 0-3
Oligometastases (1-3) with aggregate tumor diameter 2.5 g/dL Serum levels of liver enzymes 6 cm
Prior radiotherapy to the liver
Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females
Patients with psychiatric or addictive disorder that would preclude obtaining informed consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01347333). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.